360° SearchNetwork Hot Spots Trends Time Series

aldesleukin

Type: Keyphrase

Name: aldesleukin

First reported May 09 2013 - Updated May 09 2013 - 1 reports

Prometheus Laboratories Inc. Launches PROCLIVITY(SM) 01 Clinical Trial of Proleukin® (Aldesleukin for Injection) Plu

/PRNewswire/ -- Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, announces that PROCLIVITY 01, a multi-center study of Proleukin(®) (High Dose Interleukin-2 (HD IL-2))[1] plus vemurafenib therapy in patients with BRAF( ... [Published NewsBlaze - May 09 2013]

Entities: Vemurafenib, Proleukin, IL-2

First reported Apr 30 2013 - Updated Apr 30 2013 - 1 reports

Metastatic Lung Cancer - Pipeline Review, H1 2013

Research and Markets has announced the addition of the "" report to their offering. '', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Metastatic Lung Cancer, complete ... [Published Individual.com - Apr 30 2013]

Entities: Metastatic, Lung Cancer, Therapeutics, aldesleukin

First reported Apr 20 2013 - Updated Apr 20 2013 - 1 reports

New study investigates cancer drug as a treatment for type 1 diabetes

A new study funded by JDRF will carry out research to see if an existing medication that is used to treat cancer may help to prevent cells in the pancreas from being destroyed in newly diagnosed patients with . The drug which will be tested is aldesleukin. ... [Published Diabetes.co.uk - Apr 20 2013]

Entities: Diabetes Type I, antineoplastic, aldesleukin, Pancreas

First reported Apr 09 2013 - Updated Apr 09 2013 - 1 reports

Nektar demonstrates positive preclinical data for NKTR-214 for treatment of multiple cancers

Nektar Therapeutics has demonstrated positive preclinical data for NKTR-214, a novel cancer immunotherapy which targets the IL-2 receptor complex, at the 2013 American Association for Cancer Research (AACR) Annual Meeting. NKTR-214 is a new immunocytokine ... [Published PharmaBiz - Apr 09 2013]

Entities: IL-2, Receptor, Nektar Therapeutics Inc, Tumor

Quotes

...been limited until the past 2 years," stated James Lowder, MD, Senior Director of Oncology Clinical Development and Medical Affairs at Prometheus. "Immune-based therapy with the FDA-approved HD IL-2 has long been shown to produce meaningful and durable responses in a small percentage of patients with metastatic melanoma.[2] The recently FDA-approved vemurafinib produces rapid, but temporary, reductions in tumor size in a majority of patients with an activating mutation of the BRAF signaling protein. The rationale for the PROCLIVITY 01 trial is based on data suggesting that the activity of vemurafenib and IL-2 is potentially synergistic." [3]

Prometheus Laboratories Inc. Launches PROCLIVITY(SM) 01 Clinical Trial of Proleukin® (Aldesleukin ... [Published NewsBlaze - May 09 2013]

Research and Markets has announced the addition of the "" report to their offering. " provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Metastatic Lung Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Metastatic Lung Cancer. Scope - A snapshot of the global therapeutic scenario for Metastatic Lung Cancer. - A review of the Metastatic Lung Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Metastatic Lung Cancer pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Involved in Metastatic Lung Cancer Therapeutics Development - The University of Texas M D Anderson Cancer Center - Targa Therapeutics Corp. Drug Profiles - CpG DNA Lipoplex - VEGF/rGel - CNVN-202 - aldesleukin - Sticky siRNA - DT-310 For more information visit Research and Markets CONTACT: Research and Markets, Laura Wood, Senior Manager. press@researchandmarkets.com Fax from USA: 646-607-1907 Fax from rest of the world: +353-1-481-1716 Sector: Oncology (http://www.researchandmarkets.com/categories.asp?cat_id=122&campaign_id=fx664g)"

Metastatic Lung Cancer - Pipeline Review, H1 2013 [Published Individual.com - Apr 30 2013]

...senior vice president and chief scientific officer of Nektar Therapeutics. "NKTR-214 is specifically designed to harness the potent immunostimulatory effects of the IL-2 receptor complex while minimizing the immunosuppressive effects that have greatly limited the efficacy of the native IL-2 protein. Importantly, NKTR-214 represents the first application of our technology platform to target a receptor subtype in the tumor microenvironment while avoiding the unwanted effects from off-target receptor binding. NKTR-214 also has improved pharmacokinetics and enhanced tumor penetration which allow for a ten-fold reduction in overall dosing. We are excited about the potential of NKTR-214 to emerge as a powerful new immunotherapy in the fight against cancer."

Nektar demonstrates positive preclinical data for NKTR-214 for treatment of multiple cancers [Published PharmaBiz - Apr 09 2013]